About Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ATRA
- Previous Close: $14.80
- 50 Day Moving Average: $14.87
- 200 Day Moving Average: $17.54
- 52-Week Range: $12.45 - $25.73
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.52
- P/E Growth: 0.00
- Market Cap: $427.13M
- Outstanding Shares: 28,860,000
- Beta: 1.43
- Return on Equity: -27.80%
- Return on Assets: -26.80%
Companies Related to Atara Biotherapeutics:
- Current Ratio: 20.63%
- Quick Ratio: 20.63%
What is Atara Biotherapeutics' stock symbol?
Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."
Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2017?
6 analysts have issued 12-month price targets for Atara Biotherapeutics' stock. Their forecasts range from $10.00 to $47.00. On average, they anticipate Atara Biotherapeutics' share price to reach $27.33 in the next year.
When will Atara Biotherapeutics announce their earnings?
Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Atara Biotherapeutics stock?
Atara Biotherapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (18.57%), FMR LLC (9.64%), Arrowpoint Asset Management LLC (5.41%), State Street Corp (2.08%), Artal Group S.A. (1.73%) and Alyeska Investment Group L.P. (1.41%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Eric Dobmeier, Gad Soffer, Isaac E Ciechanover, Joel S Marcus, John Mcgrath and Mitchall G Clark.
Who sold Atara Biotherapeutics stock? Who is selling Atara Biotherapeutics stock?
Atara Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and RTW Investments LP. Company insiders that have sold Atara Biotherapeutics stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Gad Soffer, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark.
Who bought Atara Biotherapeutics stock? Who is buying Atara Biotherapeutics stock?
Atara Biotherapeutics' stock was acquired by a variety of institutional investors in the last quarter, including 12 West Capital Management LP, Artal Group S.A., Arrowpoint Asset Management LLC, State Street Corp, EcoR1 Capital LLC, Elkfork Partners LLC, Dimensional Fund Advisors LP and Alyeska Investment Group L.P.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier and Joel S Marcus.
How do I buy Atara Biotherapeutics stock?
Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Atara Biotherapeutics stock cost?
One share of Atara Biotherapeutics stock can currently be purchased for approximately $14.80.